High Levels of Circulating Soluble Receptors for Tumor Necrosis Factor in Hairy Cell Leukemia and Type B Chronic Lymphocytic Leukemia

Werner Digel, Franz Porzsolt, Mathias Schmid, Friedhelm Herrmann, Werner Lesslauer, and Manfred Brockhaus

Department of Internal Medicine III, University of Ulm, D-0000 Ulm, Federal Republic of Germany; Department of Internal Medicine I, University of Freiburg, D-7800 Freiburg, Federal Republic of Germany; and Central Research Units, Hoffmann-La Roche, Basel, CH-4002 Switzerland

Abstract

The presence of soluble tumor necrosis factor (TNF) binding proteins (BP) was investigated in the sera of healthy volunteers and cancer patients. Two distinct types of TNFBP, types A and B, which are immunologically related to the corresponding 75-kD TNF receptor (TNFR) and the 55-kD TNFR, respectively, were assessed by immunoassays using nonblocking anti-receptor antibodies and 125I-recombinant human TNFα. As compared to the titers observed in 25 healthy controls, TNFBP types A and B titers were found to be elevated in almost all sera obtained from patients with underlying malignant disease. The highest amounts of TNFBP were seen in the sera of patients with B cell malignancies including hairy cell leukemia (HCL) and type B chronic lymphocytic leukemia. Treatment of HCL patients with recombinant human interferon-α was associated with decrease of circulating TNFBP. (J. Clin. Invest. 1992. 89:1690–1693.) Key words: B-cell malignancies • serum • interferon therapy • tumor necrosis factor binding protein

Introduction

Tumor necrosis factor (TNF) is a pleiotropic cytokine that plays a major role in inflammation and host defense to infection (1, 2). It exerts antitumor activity in vivo as demonstrated in certain transplanted mouse tumor models (for reviews, see references 1 and 3). In the context of other factors present, TNF acts as an antileukemic agent (4) or stimulates leukocyte growth in patients with hairy cell leukemia (HCL), type B chronic lymphocytic leukemia (B-CLL) (5–7), and acute myelogenous leukemia (8–10). Recently, two distinct types of cellular TNF receptors (TNFR) have been identified by molecular cloning (11–13) and have been shown to be differentially expressed on various human cells (14). Non–cross-reactive monoclonal antibodies (MAB) have been prepared against both the 75-kD type A TNF receptor (TNFR) and the 55-kD type B TNFR (MAB series) (14), and it has been demonstrated that both types of TNFR share a high degree of amino acid sequence homology which is, however, restricted to the extracellular domain of the molecules (15). Human urine and serum contain a TNF inhibitory activity. Molecular cloning identified this molecule as soluble fragments of both TNFR (16, 17). In the following we refer to these soluble fragments of TNF as TNF binding proteins (TNFBP) types A and B. In this article, we describe a sensitive assay to detect TNFBP in human serum collected from healthy subjects and patients with a variety of mostly hematopoietic malignancies. Circulating TNFBP levels were found increased in almost all patients’ sera as compared to normal controls. Patients with HCL and B-CLL disclosed the highest TNFBP serum levels, particularly of the type A, that decreased during effective recombinant human interferon-α (rhIFNα) therapy.

Methods

Patients. We studied sera from 167 patients with malignant disorders including hematopoietic neoplasias (n = 137) and other tumor types (n = 30). Sera from 25 healthy age-matched subjects served as controls. In selected experiments, sera collected from patients with HCL were also studied during therapy with rhIFNα. All healthy controls and patients investigated were free of concomitant illness, particularly infectious disease. Informed consent was obtained in accordance with our institutional policy.

Serum samples. Blood obtained by venipuncture was allowed to clot at room temperature for 1 h; after centrifugation the serum was stored in volumes of ~ 0.5 ml at −70°C until used.

Antibodies. MAB raised against partially purified TNFR from HL60 cells (htr series) and U937 cells (utr series) were previously described (14). MAB htr-20 specifically binds to the p55 TNFR (type B) without inhibiting TNF binding (M. Brockhaus, unpublished data). Similarly, utr-4 is a noninhibitory antibody against the p75 TNFR (type A) (14).

TNFR assay. Sera were diluted 1:20 with a 1% solution of fat-free milk powder in 50 mM Tris-HCl, pH 7.4, 5 mM sodium EDTA, 140 mM sodium chloride, and 0.02% sodium azide (blocking buffer). 96-well polystyrene microtiter plates (Dynatech Laboratories, Inc., Alexandria, VA) were sensitized with affinity-purified rabbit anti-mouse immunoglobulin (10 μg/ml) followed by overnight incubation with spent culture medium from the hybridomas htr-20 or utr-4. The wells were washed once with PBS and incubated for 3 h at 4°C with the diluted serum samples. After three washings with PBS the
wells were incubated with radioiodinated rhTNFα (50 μl, 7 x 10^6 cpm/ml, sp act 450 Ci/mM) in blocking buffer for 2 h at 4°C. The wells were washed four times with PBS and bound 125I-rhTNFα was determined by gamma scintillation counting.

The TNFBP concentration was expressed as picomole per liter 125I-rhTNFα binding capacity in serum. The background was not subtracted. Unspecific binding of 125I-rhTNFα in the presence of an excess of unlabeled competitor TNFα was < 40 pM. The assays were linear for TNFBP in the reported range (not shown). The addition of exogenous rhTNFα (10 ng/ml) to the serum decreased the measured TNFBP concentration by ~ 30% also in the samples with elevated TNFBP (data not shown).

Data analysis. Data are expressed as mean±SE if not otherwise indicated. Data analysis was performed with Tukey's studentized one-way analysis of variance with simultaneous comparisons of groups and 5% was chosen as level of significance.

Results

TNFBP in serum. Soluble TNFBP of both types A and B were detected at low concentrations (79±14 and 61±12 pM, respectively) in the sera of healthy individuals (Fig. 1). From these data a 100 pM TNF binding capacity was considered as the upper normal limit for both TNFBP. Under the assumption of a 1:1 molar stoichiometry of the TNF/TNFBP complex and an average molecular mass of 30 kD for TNFβ, this cutoff is equivalent to a TNFBP concentration of 3 ng/ml. Almost all sera from the disease groups contained concentrations of type A TNFBP (150 of 167 patients) and type B TNFBP (159 of 167 patients) above level of healthy controls, P < 0.0001. The highest levels of TNFBP, predominantly of type A were detected in HCL (1,291±829 pM) and B-CLL patients (576±603 pM) (Fig. 1). Statistical comparisons of groups showed a significant difference of type A TNFBP but not type B TNFBP between the HCL group and B-CLL patients as well as between both disease entities on the one hand and the other malignancies on the other hand (P < 0.05). All 33 HCL patients investigated displayed elevated TNFBP, although the concentration of TNFBP did, however, not clearly correlate with the disease stage according to the classification of Janssen and Hermans (18) in HCL or to the Rai classification (19) in CLL (data not shown).

Decrease of TNFBP during rhIFNa therapy. We also determined both forms of TNFBP in serum of six HCL patients during treatment with rhIFNa. The serum levels of both TNFBP began to decrease several weeks after initiation of IFNa therapy (Fig. 2), and the decrease was most pronounced in patients presenting with very high type A TNFBP concentrations before treatment. At the time of TNFBP measurement during IFNa therapy the patients were all in complete (patients 2, 4, and 6) or partial (patients 1, 3, and 5) remission.

TNFBP type A decreased in all patients during therapy between 276 and 2,890 pM. In two patients with untreated stable

Figure 1. TNFBP in the serum of healthy individuals and patients with various malignancies (1 = normal controls, 2 = HCL, 3 = B-type CLL, 4 = multiple myeloma, 5 = acute myelogenous leukemia, 6 = non-B-cell acute lymphoblastic leukemia, 7 = chronic myelogenous leukemia, 8 = myelodysplastic syndrome 9 = solid tumors, 10 = other hematologic diseases [Hodgkin's disease, T-cell-lymphoma]). Type A TNFBP was detected by using anti-TNFR MAb utr-4 (top) and type B TNFR by using anti-TNFR MAb htr-20 (bottom) and 125I-rhTNF as described in Methods. Bound 125I-rhTNF is expressed as TNF binding capacity in picomoles of TNF per liter of serum. The horizontal lines indicate the mean values. The data points represent single determinations.
and after 6 mo of treatment with rhIFNa (stippled bars). Type A (top) and type B TNFBP (bottom) are measured as described in Methods and expressed as TNF binding capacity in picomoles of TNF per liter of serum. Patients 2, 4, and 6 were in complete remission after rhIFNa treatment (<5% hairy cells in a bone marrow core biopsy and improvement in peripheral counts with Hb > 12 g/dl, platelets > 100,000/µl, neutrophils > 1,500/µl), whereas patients 1, 3, and 5 were in partial remission (>5% hairy cells in the bone marrow core biopsy but at least a 50% decrease from baseline, and improvement in peripheral counts) after rhIFNa treatment.

disease no similar reduction was found. The serum concentration of TNFBP remained constant at a low level for an observation period of 72 wk (data not shown).

Discussion

We have analyzed the sera of 167 patients with both hematologic and nonhematologic malignancies for the presence of TNFBP. A sandwich type of immunoassays using immobilized anti-TNF MAb and 125I-rhTNFα allowed us to specifically determine types A and B TNFBP that are antigenically equivalent to the 75-kD TNFR (MAb utr-4) and the 55-kD TNFR (MAb htr-20), respectively. A significant increase of the mean TNFBP serum concentration was detected in all patient groups, but the most notable result was the exceptionally high TNFBP concentrations with predominance of type A over type B TNFBP in the sera of most HCL and B-CLL patients. In experimental edotoxinemia in healthy subjects only a maximal fivefold increase of both types A and B TNFBP levels were observed (20). The cellular source of TNFBP in HCL and B-CLL is presently unknown. However, we observed that levels of TNFBP decreased in HCL during effective rhIFNa therapy, suggesting a correlation of circulating TNFBP with tumor cell load. However, TNFBP serum concentrations were not correlated with clinical staging of HCL and B-CLL (18, 19). TNF has been found to be produced by HCL and B-CLL cells (5, 7, 21) and to stimulate proliferation of HCL and B-CLL cells in vitro (5, 6). It is possible that TNF serves as an autocrine growth factor in both disease states and thus TNFBP may play an important role in the regulation of neoplastic cell growth in HCL and B-CLL. It is of note, however, that more mature B-cell malignancies such as multiple myeloma failed to exhibit increased type A TNFBP levels.

In most other malignancies elevated serum concentrations of predominately type B TNFBP with a fairly constant ratio of type B to type A proteins were disclosed. Therefore we assume that the TNFBP in these cases are not produced by the neoplastic cells themselves. It has, for instance, been shown that neutrophiles are a potent source of TNFBP when activated (22). The existence of circulating soluble forms of cytokine receptor proteins applies for a variety of other cytokine receptors as well. In contrast, however, to the soluble IL-2, IL-4, or IL-7 receptors (23, 24), soluble TNFR are most likely the products of posttranslational processing of the TNFR molecules (11, 15–17).

Once in systemic circulation, soluble receptor protein fragments such as TNFBP can compete with cell-bound receptors for ligand. They may thus form a pool of scavenger molecules which neutralize highly toxic cytokines such as TNF. More complex functions for soluble receptor fragments are conceivable, if, e.g., the existence of membrane-bound TNF is taken into account. From a practical point of view, combined measurements of TNF and inhibiting TNFBP, rather than that of TNF alone, will provide an additional important parameter of the cytokine status in a given clinical situation.

Acknowledgments

We thank Drs. Hansruedi Loetscher and Werner Haas for valuable comments during this work and for their critical reading of the manuscript.

This study was supported by the grant from the Dr. Mildred Scheel Foundation to Dr. Herrmann.

References


